1.Research progress in quality control materials used for non-invasive prenatal testing
Tingting LUO ; Yan ZENG ; Yandi QIAN
Chinese Journal of Laboratory Medicine 2024;47(5):585-588
Non-invasive prenatal testing (NIPT) is a prenatal screening method that uses high-throughput gene sequencing technology to detect fetal free DNA fragments in maternal peripheral blood, in order to evaluate the risk of common chromosomal aneuploidy (T21, T18, T13) in fetuses. It has made great contributions to the prevention and treatment of birth defects. To ensure the accuracy and reliability of the testing results, it is necessary to add quality control materials for strict quality control throughout the entire testing process . However, most testing platforms lack plasma quality control materials during plasma extraction. Universal plasma quality control materials are also needed in the external quality assessment on different platforms. To solve this quality control problem, six strategies for the preparation of NIPT plasma control materials have emerged in recent years, with different application ranges, advantages and disadvantages based on their different sources of matrix and positive DNA.
2.Development of plasma quality control material for non-invasive prenatal detection of fetal aneuploidy
Yan ZENG ; Tao ZHANG ; Yandi QIAN ; Yuling GAO ; Cheng XIONG ; Yunqin NI ; Tingting LUO ; Lifang ZHANG ; Feiyan QIAN
Chinese Journal of Laboratory Medicine 2022;45(5):444-448
Objective:To develop a self-made plasma quality control material for non-invasive prenatal testing (NIPT) and evaluate its performance.Methods:139 NIPT-negative maternal plasmas stored in the genetic department of Shaoxing maternal and child health hospital from January 1, 2019 to June 30, 2021 were divided into male groups (19 cases) and female groups (120 cases) according to the neonatal gender. 9360 cases from September 2020 to September 2021 were enrolled as clinical validation cases.First step, 200 μl plasma from a 47 years-old non-pregnant healthy women was used as a matrix. Different amounts (0.1, 0.2, 0.5, 2.5, and 5 μl) of positive DNA from fetal chromosome aneuploidy (T21, T18, T13) detection kit were added. The appropriate volume of positive DNA was 0.5 μl according to the test results. Second step,Plasma in male and female group was treated as matrix. 0.5 μl positive DNA was added per 205 μl. Plasma matrix from female group showed good repeatability and the sensitivity was 100%.Third step, evaluate the self-made plasma quality control material, including storage stability, matrix uniformity and repeatability, and the effect of different batch numbers of positive DNA, by calculating Z score and the CV of fetal DNA concentration (FF).Results:Plasma matrix from female group showed good repeatability and the sensitivity was 100%, while the sensitivity of male group was only 84%. The CV of FF in female matrix was 3.9% in the repetitive experiments. After adding 0.5 μl positive DNA, the mean FF of self-made positive plasma quality control was 5.63%±0.42%, Z values>6, and the CV was 7% after storage of three months. Considering the concentration variation of positive DNA in different lots, 1 μl of positive DNA should be added when the FF of positive DNA is lower than 10%.Used in 9360 clinical cases from September 2020 to September 2021, all positive plasma quality control materials showed positive results, and the positive predictive value of trisomy 21 was 100%.Conclusions:The NIPT self-made positive plasma quality control material has been successfully developed in this study. The preliminary experimental results show that it has good repeatability and stability, which is suitable for clinical application.